Last reviewed · How we verify

Prednisone, Dexamethasone, Vincristine, Daunorubicin

St. Jude Children's Research Hospital · Phase 3 active Small molecule

Prednisone, Dexamethasone, Vincristine, Daunorubicin is a Multi-agent chemotherapy regimen Small molecule drug developed by St. Jude Children's Research Hospital. It is currently in Phase 3 development for Acute lymphoblastic leukemia (ALL) in children, Acute myeloid leukemia (AML) in children.

This is a multi-drug chemotherapy regimen that combines corticosteroid immunosuppression, alkylating agents, and cytotoxic chemotherapy to treat acute leukemia by suppressing immune response and killing rapidly dividing cancer cells.

This is a multi-drug chemotherapy regimen that combines corticosteroid immunosuppression, alkylating agents, and cytotoxic chemotherapy to treat acute leukemia by suppressing immune response and killing rapidly dividing cancer cells. Used for Acute lymphoblastic leukemia (ALL) in children, Acute myeloid leukemia (AML) in children.

At a glance

Generic namePrednisone, Dexamethasone, Vincristine, Daunorubicin
SponsorSt. Jude Children's Research Hospital
Drug classMulti-agent chemotherapy regimen
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Prednisone is a corticosteroid that suppresses immune function and reduces inflammation. Dexamethasone is a potent corticosteroid with similar immunosuppressive effects. Vincristine is a vinca alkaloid that arrests cells in metaphase by disrupting microtubule formation. Daunorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, causing DNA damage and cell death. Together, these agents target leukemic blasts through multiple mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Prednisone, Dexamethasone, Vincristine, Daunorubicin

What is Prednisone, Dexamethasone, Vincristine, Daunorubicin?

Prednisone, Dexamethasone, Vincristine, Daunorubicin is a Multi-agent chemotherapy regimen drug developed by St. Jude Children's Research Hospital, indicated for Acute lymphoblastic leukemia (ALL) in children, Acute myeloid leukemia (AML) in children.

How does Prednisone, Dexamethasone, Vincristine, Daunorubicin work?

This is a multi-drug chemotherapy regimen that combines corticosteroid immunosuppression, alkylating agents, and cytotoxic chemotherapy to treat acute leukemia by suppressing immune response and killing rapidly dividing cancer cells.

What is Prednisone, Dexamethasone, Vincristine, Daunorubicin used for?

Prednisone, Dexamethasone, Vincristine, Daunorubicin is indicated for Acute lymphoblastic leukemia (ALL) in children, Acute myeloid leukemia (AML) in children.

Who makes Prednisone, Dexamethasone, Vincristine, Daunorubicin?

Prednisone, Dexamethasone, Vincristine, Daunorubicin is developed by St. Jude Children's Research Hospital (see full St. Jude Children's Research Hospital pipeline at /company/st-jude-children-s-research-hospital).

What drug class is Prednisone, Dexamethasone, Vincristine, Daunorubicin in?

Prednisone, Dexamethasone, Vincristine, Daunorubicin belongs to the Multi-agent chemotherapy regimen class. See all Multi-agent chemotherapy regimen drugs at /class/multi-agent-chemotherapy-regimen.

What development phase is Prednisone, Dexamethasone, Vincristine, Daunorubicin in?

Prednisone, Dexamethasone, Vincristine, Daunorubicin is in Phase 3.

What are the side effects of Prednisone, Dexamethasone, Vincristine, Daunorubicin?

Common side effects of Prednisone, Dexamethasone, Vincristine, Daunorubicin include Myelosuppression (neutropenia, thrombocytopenia, anemia), Infection, Mucositis, Nausea and vomiting, Alopecia, Cardiotoxicity (daunorubicin-related).

Related